A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas.
Bowen LiJiu WangFangfang LiuRui LiWeihong HuAmandine EtcheverryMarc AubryJean MosserAn-An YinXiang ZhangYuanming WuKun ChenYa-Long HeLi WangPublished in: Journal of oncology (2022)
The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.